Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

Research output: Contribution to journalArticlepeer-review


  • Vera Hirsh
  • Luis Paz-Ares
  • Michael Boyer
  • Rafael Rosell
  • Wilfried E E Eberhardt
  • Aleksandra Szczesna
  • Pavel Reiterer
  • Mansoor Saleh
  • Oscar Arrieta
  • Emilio Bajetta
  • Roy T Webb
  • Johannes Raats
  • Rebecca J Benner
  • Camilla Fowst
  • Sandra J Meech
  • David Readett
  • Joan H Schiller

Colleges, School and Institutes


This phase III study examined efficacy of the synthetic Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 in combination with standard paclitaxel/carboplatin chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC).


Original languageEnglish
Pages (from-to)2667-74
Number of pages8
JournalJournal of Clinical Oncology
Issue number19
Publication statusPublished - 2011